Treatment outcomes of molecular targeted therapy following nivolumab in metastatic renal cell carcinoma
ConclusionsMolecular targeted therapies following nivolumab had comparatively better therapeutic efficacy, which was confirmed regardless of the type of molecular targeted agent used.
Source: Japanese Journal of Clinical Oncology - Category: Cancer & Oncology Source Type: research
More News: Cancer & Oncology | Carcinoma | Japan Health | Kidney Cancer | Renal Cell Carcinoma | Study